Abstract
Development of an HIV vaccine presents a formidable challenge. One of the unresolved, yet central issues is the importance of HIV variability. Here we argue that even with the recent focus on the induction of T cell-mediated immunity, HIV vaccines should match the local circulating HIV clades. Whether used alone or in a combination with vaccines eliciting HIV-neutralizing antibodies, efforts must be made to develop a T cell vaccine that stimulates a broad and long-lasting response.
MeSH terms
-
AIDS Vaccines*
-
Amino Acid Sequence
-
Animals
-
Antigen Presentation
-
Antigenic Variation*
-
Clinical Trials, Phase I as Topic
-
Epitopes / immunology
-
HIV / classification*
-
HIV / genetics
-
HIV / immunology
-
HIV Antibodies / biosynthesis
-
HIV Antigens / chemistry
-
HIV Antigens / genetics
-
HIV Antigens / immunology*
-
HIV Infections / epidemiology
-
HIV Infections / virology
-
HLA Antigens / immunology
-
Humans
-
Immunity, Cellular
-
Immunologic Memory
-
Interleukin-2 / immunology
-
Kenya / epidemiology
-
Macaca
-
Mice
-
Neutralization Tests
-
Structure-Activity Relationship
-
T-Lymphocytes, Cytotoxic / immunology*
-
Vaccines, DNA
-
Vaccines, Synthetic
Substances
-
AIDS Vaccines
-
Epitopes
-
HIV Antibodies
-
HIV Antigens
-
HLA Antigens
-
Interleukin-2
-
Vaccines, DNA
-
Vaccines, Synthetic